Gastric Cancer - US Drug Forecasts and Treatment Analysis to 2020 - Global Data, the industry analysis specialist, has released its new report, "Gastric Cancer - US Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the US gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the US gastric cancer therapeutics market. It analyses the treatment usage patterns in the US gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the US gastric cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Data's team of industry experts.
- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized US gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in US.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the US Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the US gastric cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the US gastric cancer therapeutics market till 2020.
- Quantifying patient population in the US gastric cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the US gastric cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the US gastric cancer therapeutics market landscape? Identify, understand and capitalize